Blue Jet Healthcare (BLUEJET) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue from operations was ₹1,628.99 mn, down 9.3% YoY and 11.4% QoQ; profit for the period was ₹377.77 mn, down 14.4% YoY.

• Red Sea shipping delays deferred recognition of dispatched contrast-media sales; Q1 production and dispatches exceeded Q4.

• Plant 6 at Ambernath was commissioned with 120 KL of pharma-intermediate capacity after ₹900 mn investment; treasury investments and cash totaled ₹3,781 mn at June 2024.

• Auditor review found no indication of material misstatement or non-compliance with required disclosures.

Financial highlights

• Revenue from operations was ₹1,628.99 mn versus ₹1,795.41 mn in Q1 FY24; total income was ₹1,716.14 mn versus ₹1,846.04 mn.

• EBITDA was ₹443 mn, down 24.9% YoY and 16.6% QoQ; EBITDA margin was 27.2%, versus 32.8% in Q1 FY24 and 28.8% in Q4 FY24.

• PAT was ₹377.77 mn versus ₹441.21 mn YoY; PAT margin was 23.2%, versus 24.6% in Q1 FY24 and 21.6% in Q4 FY24, with PAT up 2% QoQ.

• Gross profit was ₹891 mn, down 11.2% YoY; gross margin improved to 54.7% from 53.3% in Q4 FY24.

• At least 50% of quarterly turnover in shipped goods awaited sales recognition; only partial spillover was expected in the next quarter.

Outlook and guidance

• Contrast-media dispatches were expected to remain at Q1 levels through December, with higher customer offtake anticipated from January and a higher customer forecast next year.

• Cardiovascular-intermediate supply ramp-up from Q3 was on track after successful validation batches, with orders in hand and no expected delay.

• Strategy prioritizes R&D, operational efficiency, supply-chain risk mitigation and production capacity; plans include advanced contrast-media intermediates and adjacent pharma-intermediate and API opportunities.

• Management gave no quantified growth guidance, citing an interesting order book and capacity plans aligned with customer forecasts and visibility; it aims to sustain current EBITDA and PAT margins as products scale.